Boston Scientific Corporation BSX

43.92 (0.76) (1.70%) as of 25 Sep
Market cap
$64.7B
P/E
17.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Boston Scientific Corporation (BSX) Gross margin

Boston Scientific Corporation's gross margin over the twelve months to 30 June 2026 was 69.9%, up 0.9 percentage points from fiscal 2025 (69.0%). Over the past ten years it has ranged from 65.1% (fiscal 2020) to 71.4% (fiscal 2018); the current reading is higher than 45% of that period. That is above the Medical Devices industry median of 56.0% and above the Healthcare sector median of 53.7%.

Gross margin, annual

Annual

Period Gross margin Change (points)
FY2025 69.0% 0.40
FY2024 68.6% (0.88)
FY2023 69.5% 0.68
FY2022 68.8% 0.03
FY2021 68.8% 3.73
FY2020 65.1% (5.92)
FY2019 71.0% (0.39)
FY2018 71.4% 0.02
FY2017 71.3% 0.25
FY2016 71.1% 0.15

Quarterly

Period Gross margin Change (points)
Jun 2026 70.7% 1.27
Mar 2026 69.4% (0.13)
Dec 2025 69.6% (0.36)
Sep 2025 69.9% 2.28
42 more quarters

Against its own ten years

Low 65.1% High 71.4%
Ten-year median 69.5%
Current reading's percentile 45

Gross margin against peers

Company Gross margin
EW Edwards Lifesciences Corporation compare 77.8%
BSX Boston Scientific Corporation 69.9%
MDT Medtronic PLC compare 65.0%
SYK Stryker Corporation compare 65.0%
DXCM DexCom, Inc. compare 62.5%
ABT Abbott Laboratories compare 56.6%
PHG Koninklijke Philips N.V. compare 45.9%
STE STERIS plc compare 44.4%
GEHC GE HealthCare Technologies Inc. compare 39.5%
Medical Devices industry median 56.0%
Healthcare sector median 53.7%
Market median 46.3%

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on BSX